Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 250 results for "Victoza"

Did Victoza for Diabetes Damage the Pancreas?
Peoples Pharmacy

ADA: Empagliflozin and liraglutide reduce type 2 CV death

FROM DIABETES CARE Empagliflozin (Jardiance) and liraglutide (Victoza) should be considered in type 2 diabetes patients with documented cardiovascular disease to reduce the risk of CV death, according to the American Diabetes Association 2017 ... PM 360, 3 weeks ago
Did Victoza for Diabetes Damage the Pancreas? Peoples Pharmacy, 1 month ago

10 images for Victoza

Endocrinology Advisor, 1 month ago
Peoples Pharmacy, 1 month ago
Pharma Letter, 1 month ago
Pharma Letter, 4 months ago
DataMonitor HealthCare, 3 months ago
Pharma Letter, 3 months ago
BioPharma Dive, 4 months ago
FiercePharma, 5 months ago
Pharmafile, 5 months ago
FiercePharma, 6 months ago

Sanofi diabetes combo approved in EU

Sanofi's type 2 diabetes combination drug Suliqua has been approved in Europe setting the scene for a showdown with Novo Nordisk's rival, Xultophy. The EU approval means Sanofi and Novo Nordisk both have competing combination therapies approved ...
 pharmaphorum10 hours ago Novo, Sanofi get same-day approval for diabetes drug combos  BioPharma Dive1 month ago
Ticker Report

Price-Fixing Claims Pressed in Novo Nordisk Shareholder Suits

Danish drugmaker Novo Nordisk is facing two shareholder class actions in federal court accusing it of inflating its earning prospects and engaging in collusive pricing of its insulin drugs for diabetics. The latest suit, Zuk v. Novo Nordisk , was ...
 New Jersey Law Journal21 hours ago Novo Nordisk: Key Threats In 2017 And Beyond  Seeking Alpha23 hours ago Novo Nordisk A/S (NVO) Upgraded to Hold at Zacks Investment Research  Ticker Report1 week ago Novo Nordisk A/S (NVO) Rating Increased to Hold at Zacks Investment Research  SleekMoney2 weeks ago
[x]  

ADOCIA : Announces the Transformation of Its Business Model to Increase the Value of Its Projects

With its experience on BioChaperone ® Lispro, Adocia intends to develop its projects further, at least to Phase 3 Three new projects targeting major markets are expected to enter clinical trials this year Adocia's portfolio of projects is one of ...
 4 Traders1 day ago

[SHINSA]English Translation of Review Report: Xiaflex

Here begins the text. The following English translations of review reports are intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese originals and the translations, the former ...
 PMDA.go.jp1 week ago

The Threats And Opportunities In NASH: What Next For Allergan?

Allergan stepped in the NASH space with the acquisitions of Tobira and Akarna announced in November 2016 for around $650M of upfront payment plus additional milestones. I like the portfolio approach adopted by Allergan's management in NASH, and I ...
 Seeking Alpha1 week ago
FiercePharma

Top 20 pharma brands dropped more than $2B on national TV ads last year

Pharma companies spent $2.2 billion last year on TV ads for their 20 top brands, and nine of the biggest spenders each went over $100 million with their national media budgets, according to data from real-time TV ad tracker iSpot.tv. Of course, ...
 FiercePharma1 week ago
Nasdaq

Novo Nordisk (NVO) Fiasp Gets EU Nod for Diabetes in Adults

Novo Nordisk A/S NVO announced that its fast-acting insulin aspart, Fiasp, has been approved in the EU for the treatment of diabetes in adults. A look at Novo Nordisk's share price movement in the past one year shows that the company has ...
 Yahoo! Canada1 week ago Novo Nordisk: Why The Diabetes Giant Will Continue To Grow  Seeking Alpha1 month ago
[x]  
Motley Fool

The 1 Biotech Stock I Want to Own in 2017

For most biotechs about to turn the profitability corner, launching the first ever treatment for the most common genetic cause of infant mortality might be their biggest headline of the year. But, the launch of Spinraza is just the beginning of a ...
 Motley Fool1 week ago
FierceBiotech

Intarcia's Implantable Type 2 Diabetes Therapy Submitted to the FDA

By Helen Gao, Payal Marathe, and Lynn Kennedy Continuously delivers GLP-1 agonist for 3-6 months; FDA decision is expected by the end of 2017 Intarcia, a growing biopharmaceutical company focused on chronic disease prevention and management, ...
 diaTribe1 week ago 2016's new drug approvals don't measure up to 2015's  FierceBiotech2 weeks ago Conference Stories That Captivated AJMC┬« Readers in 2016  American Journal of Managed Care3 weeks ago Quiz Yourself: What Was the Top Endo News of 2016?  General Medicine eJournal3 weeks ago
[x]  
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less